The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus

被引:0
|
作者
Parlar, Mehmet Akif [1 ]
Mutlu, Hakan [1 ]
Dogantekin, Betul [1 ]
Musaoglu, Ismail Serhat [1 ]
Albayrakoglu, Nisa Demirbosnak [1 ]
Yavuz, Mustafa Lutfi [2 ]
Ozbolat, Zehra Busra [3 ]
Kaplan, Mustafa [1 ]
机构
[1] Univ Hlth Sci, Sultan Abdulhamid Han Training & Res Hosp 2, Dept Internal Med, Tibbiye St, TR-34668 Istanbul, Turkiye
[2] Istanbul Univ, Fac Med, Dept Cardiol, TR-34093 Istanbul, Turkiye
[3] Cerkezkoy State Hosp, Dept Chest Dis, Tekirdag Prov Hlth Directorate, TR-59100 Tekirdag, Turkiye
关键词
diabetes mellitus; fatty pancreas; fatty liver; statin; steatosis; ADIPOSE-TISSUE INFLAMMATION; INSULIN-SECRETION; GLUCOLIPOTOXICITY; CHOLESTEROL; DYSFUNCTION; DISEASE; ATORVASTATIN; SIMVASTATIN; STEATOSIS; EFFICACY;
D O I
10.3390/diagnostics15040426
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objectives: It has been shown that the use of statins in patients with type 2 diabetes mellitus (T2DM) worsens hyperglycemia and hemoglobin A1c levels but may help in the preservation of pancreatic beta-cell function. The potential role of a high pancreatic fat fraction (PFF) in this process has not yet been clarified. This study aimed to investigate whether the liver fat fraction (LFF) and PFF in T2DM patients is affected by statin therapy. Methods: This cross-sectional study involved a total of 140 T2DM patients, including both those who were receiving (n = 70) and those who were not receiving (n = 70) statin therapy. The mapping of the LFF and PFF utilizing the IDEAL-IQ sequence was conducted in magnetic resonance imaging. Results: In T2DM patients who used statins, the median PFF was higher compared to those who did not use statins (8.4 vs. 6.2%, p = 0.021), while the median LFF was found to be similar (8.4 vs. 8.9, p = 0.572). Variations in PFF were associated with the use of various statins (non-statin group: 6.2 vs. atovastatin: 8.7 vs. rosuvastatin: 3.2 vs. pitavastatin: 9.2, p = 0.004). The multivariable regression analysis indicated that insulin usage decreased log(LFF) by a factor of 0.16-fold (beta +/- SE = -0.16 +/- 0.05, p = 0.010), and rosuvastatin usage reduced log(PFF) by 0.16-fold (beta +/- SE = -0.16 +/- 0.07, p = 0.025), irrespective of other risk factors. Furthermore, the use of atorvastatin (beta +/- SE = 0.17 +/- 0.06, p = 0.011) and pitavastatin (beta +/- SE = 0.19 +/- 0.07, p = 0.008) were independently associated with an increase in log(PFF). Conclusions: In patients with T2DM, statin use did not show a significant effect on the liver fat fraction, but it caused differences in the pancreatic fat fraction. The observation of a lower pancreatic fat fraction in patients taking a rosuvastatin and atorvastatin dose of 40 mg/day suggests that different types and doses of statins may have varying effects on pancreatic fat accumulation.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Nonalcoholic fatty liver disease in type 2 diabetes mellitus
    Cusi, Kenneth
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2009, 16 (02) : 141 - 149
  • [42] Prevalence of nonalcoholic fatty liver disease and its association with age in patients with type 2 diabetes mellitus
    Yamane, Ryosuke
    Yoshioka, Kentaro
    Hayashi, Kazuhiko
    Shimizu, Yuko
    Ito, Yuki
    Matsushita, Komei
    Yoshizaki, Michiyo
    Kajikawa, Go
    Mizutani, Taro
    Watarai, Atsuko
    Tachi, Kosuke
    Goto, Hidemi
    WORLD JOURNAL OF HEPATOLOGY, 2022, 14 (06) : 1226 - 1234
  • [43] Prevalence and Association of Elevated Liver Transaminases in Type 2 Diabetes Mellitus Patients in Jeddah, Saudi Arabia
    Alzahrani, Sami H.
    Baig, Mukhtiar
    Bashawri, Jamil, I
    Aashi, Mooataz M.
    Shaibi, Faisal K.
    Alqarni, Dalya A.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (07)
  • [44] Comparison of on-Statin Lipid and Lipoprotein Levels for the Prediction of First Cardiovascular Event in Type 2 Diabetes Mellitus
    Kim, Ji Yoon
    Choi, Jimi
    Kim, Sin Gon
    Kim, Nam Hoon
    DIABETES & METABOLISM JOURNAL, 2023, 47 (06) : 837 - 845
  • [45] Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
    Yang, Ye Seul
    Kim, Hack-Lyoung
    Kim, Sang-Hyun
    Moon, Min Kyong
    DIABETES & METABOLISM JOURNAL, 2023, 47 (01) : 1 - 9
  • [46] Statins and Risk of New-Onset Diabetes Mellitus: is there a Rationale for Individualized Statin Therapy?
    Eliano Pio Navarese
    Anna Szczesniak
    Michalina Kolodziejczak
    Bartosz Gorny
    Jacek Kubica
    Harry Suryapranata
    American Journal of Cardiovascular Drugs, 2014, 14 : 79 - 87
  • [47] Effect of Statin Therapy on Incident Type 2 Diabetes Mellitus in Patients With Clinically Manifest Vascular Disease
    van de Woestijne, Anton P.
    van der Graaf, Yolanda
    Westerink, Jan
    Nathoe, Hendrik M.
    Visseren, Frank L. J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2015, 115 (04) : 441 - 446
  • [48] Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis
    Muthiah, Mark
    Ng, Cheng Han
    Chan, Kai En
    Fu, Clarissa Elysia
    Lim, Wen Hui
    Tan, Darren Jun Hao
    Nah, Benjamin
    Kong, Gwyneth
    Xiao, Jieling
    Yong, Jie Ning
    Tan, Bryan
    Syn, Nicholas
    Wang, Jiong-Wei
    Sayed, Nilofer
    Tan, Eunice
    Chew, Nicholas W. S.
    Dan, Yock Young
    Siddiqui, Mohammad Shadab
    Sanyal, Arun J.
    Noureddin, Mazen
    ANNALS OF HEPATOLOGY, 2023, 28 (01)
  • [49] Antihypertensive therapy in diabetes mellitus-2012 guidelines of the Austrian diabetes association
    Schernthaner, Guntram
    Drexel, Heinz
    Rosenkranz, Alexander R.
    Schernthaner, Gerit-Holger
    Watschinger, Bruno
    WIENER KLINISCHE WOCHENSCHRIFT, 2012, 124 : 23 - 27
  • [50] DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus
    Kanazawa, Ippei
    Tanaka, Ken-ichiro
    Sugimoto, Toshitsugu
    MEDICAL SCIENCE MONITOR, 2014, 20 : 1662 - 1667